Search
A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe
Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.
Sep 1
ASGCT 2026: Circio's circular RNA work has been advancing and is furthest along in cardiology indications. $35M in new funding will also help accelerate plans to for the eye, CNS, and in vivo CAR-T
Erik Wiklund describes the advantages of circular RNA, and the progress the company has been making since last year's ASGCT. With partnerships and additional funding in hand since then, the company is accelerating its work in multiple dimensions. Coverage brought to you by
May 14
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies
CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered...
May 14, 2025
.png){kind=logo}